9-[3-[(1-Methylethyl)amino]propyl]-9H-fluorene-9-carboxamide

308.4 g/mol

308.42

3AZF20DM1T

DTXSID2057819

55.1 Ų

3.11 (LogP)|3.8

94-95 °C

8.96e-04 g/L

When given orally to either young adult rats or mice, the LD50 was 100 mg/kg. Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.

For the treatment of life-threatening dysrhythmias and sustained ventricular tachycardia.

Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.

Nearly complete following oral administration.

Indecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.

9-(3-((1-methylethyl)amino)propyl)-9H-fluorene-9-carboxamide

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients